UnitedHealth Group ($UNH) Faces Surge in Medical CostsUnitedHealth Group Inc. (NYSE: NYSE:UNH ), one of the largest health insurers in the United States, reported a 3% drop in share price following its Q3 2024 earnings report. The company's results highlighted an uptick in medical costs as it grapples with challenges in its insurance business, including lower government payments and persistently high healthcare demand. Let’s break down the key aspects driving the stock's recent performance.
Elevated Costs and Earnings Beat
UnitedHealth's Q3 2024 results showed a significant rise in its medical loss ratio (MLR)—the percentage of premiums used to cover medical costs. The MLR rose to 85.2%, exceeding both last year’s figure (82.3%) and analysts’ expectations of 84.2%. This surge in costs is attributed to an increase in healthcare services under Medicare plans, particularly for individuals aged 65 and older, as postponed procedures from the COVID-19 pandemic catch up. Additionally, turnover in Medicaid has left insurers with a sicker patient base, further elevating costs.
Despite these challenges, UnitedHealth delivered an adjusted profit of $7.15 per share, beating Wall Street estimates by 15 cents. The company's revenues hit $100.8 billion, surpassing the $99.28 billion expected by analysts, thanks to strong growth in its healthcare services businesses under Optum and insurance offerings under UnitedHealthcare.
Key highlights:
- Optum Health revenue grew by $2.1 billion, driven by the expansion of value-based care and in-home patient services.
- Optum Rx, the company’s pharmacy services division, saw revenue growth of $5.4 billion, fueled by new clients and expanded pharmacy offerings.
- Medicare and Medicaid pressures persisted, with the company facing government funding reductions and a sicker Medicaid population due to eligibility redeterminations.
While the overall financial performance was positive, the rise in medical costs and increased demand for healthcare services, particularly from Medicare and Medicaid plans, weighed on investor sentiment, contributing to the drop in stock price.
Technical Outlook: Bearish Signs Emerge
On the technical front, NYSE:UNH stock has entered a bearish trend following the earnings report, and it is currently down 3.54% in Tuesday’s pre-market trading. On Monday, the stock saw a 1.60% gain but quickly reversed as the negative aspects of the earnings report began to dominate market sentiment.
The stock has broken below its symmetrical triangle pattern, confirming a bearish continuation pattern. The Relative Strength Index (RSI) was 66 on Monday, indicating the stock was approaching overbought territory. However, the sharp decline in pre-market trading has relieved some of this pressure. If the bearish momentum continues, the RSI could dip below 50, signaling further downside potential.
Immediate support lies at $530, the base of the triangle pattern, where the stock may find some consolidation. The stock is currently hovering around its 50-day. A break below these levels could reinforce the bearish sentiment and signal further downside to come.
What Can Investors Expect?
From a fundamental perspective, UnitedHealth's revenue growth and earnings beat show that the company remains a leader in the healthcare sector, with its Optum businesses continuing to drive profitability. However, the elevated medical costs, particularly related to Medicare and Medicaid, could be a persistent headwind. Regulatory changes or adjustments in Medicaid enrollment could also add to volatility in the coming quarters.
On the technical side, the break below the triangle pattern is a bearish signal, and further downside toward the $530 support level seems likely if sentiment does not improve. Investors should watch for signs of consolidation at these levels or a potential breakdown, which could push the stock even lower.
Conclusion
UnitedHealth Group (NYSE: NYSE:UNH ) remains a strong company with a diverse portfolio spanning insurance and healthcare services. However, its near-term outlook is clouded by rising medical costs, Medicare funding challenges, and Medicaid enrollment fluctuations. Technically, the stock is in a bearish phase, but key support levels could provide opportunities for long-term investors if the stock consolidates or rebounds.
